<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069899</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-05</org_study_id>
    <nct_id>NCT02069899</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody</brief_title>
  <official_title>A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovImmune SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Supported by a grant of the 7th framework programme &quot;FP7&quot; from the European Committee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NovImmune SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, long-term, follow-up study that will enroll HLH patients who have
      received NI-0501 in a previous clinical trial, in the context of the clinical development
      program for NI-0501
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to monitor the long-term safety profile of patients who have
      previously received at least one dose of NI-0501, including survival at several time points
      after the administration of NI-0501.

      Moreover to study the elimination profile of NI-0501 and to assess the immunogenicity of
      NI-0501.

      Furthermore in the event that patients, upon request of the treating physician, will be
      maintained on NI-0501 treatment beyond the foreseen 8 weeks, NI-0501 safety, tolerability,
      efficacy and PK profile will be closely monitored in these patients until treatment
      discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Up to 12 months post transplant or post last dose of NI-0501</time_frame>
    <description>The incidence, intensity, possible relationship to NI-0501 and outcomes of adverse events, serious and non-serious, will be assessed throughout the study.
Vital signs, physical examination and laboratory values: evolution over time.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Efficacy endpoints</measure>
    <time_frame>Pre transplant, 30, 60, 100 days and 6, 12 months post transplant or post last dose of NI-0501</time_frame>
    <description>Survival</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <description>- NI-0501 elimination profile</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <description>IFNγ total, as long as NI-0501 can be measured
IFNγ free, as soon as NI-0501 is not detectable
Exploratory parameters/disease markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 6 months after last NI-0501 infusion</time_frame>
    <description>Presence of anti-drug antibodies (i.e. ADAs)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>NI-0501 only in case is requested</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NI-0501, in the event that, upon request of the treating physician, NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous protocol, patients will continue receiving NI-0501 in the context of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NI-0501</intervention_name>
    <description>In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous study, and upon request of the treating physician, patients will continue receiving NI-0501 in the context of this study.</description>
    <arm_group_label>NI-0501 only in case is requested</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having received at least one dose of NI-0501.

          -  Having signed the Informed Consent by the patient or the patient's legal
             representative(s), as applicable, with the assent of patients who are legally capable
             of providing it.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cristina de Min, MD</last_name>
    <phone>+41 61 201 1322</phone>
    <email>cdemin@novimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-7106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy Garrington, MD</last_name>
      <phone>720-777-6740</phone>
      <email>timothy.garrington@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Garrington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children Nemours Center for Cancer and Blood Disorders</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Powell, MD</last_name>
      <phone>302-651-5500</phone>
      <email>Jonathan.Powell@nemours.org</email>
    </contact>
    <contact_backup>
      <last_name>Debra Bertz</last_name>
      <email>Debra.Bertz@nemours.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanmuganathan Chandrakasan, MD</last_name>
      <phone>404-727-8877</phone>
      <email>shanmuganathan.chandrakasan@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Shanmuganathan Chandrakasan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara A. Degar, MD</last_name>
      <phone>617-632-5186</phone>
      <email>Barbara_Degar@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara A Degar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Kasow, MD</last_name>
      <phone>919-962-8733</phone>
      <email>kimberly_kasow@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Kimberly Kasow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital - Division of Immunobiology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jordan, MD</last_name>
      <phone>513-636-7287</phone>
      <email>Michael.Jordan@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Allen, MD, PhD</last_name>
      <phone>832-824-4312</phone>
      <email>ceallen@txch.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Diaz</last_name>
      <phone>1-832-824-1520</phone>
      <email>mldiaz@txch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carl Allen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark N Fluchel, MD</last_name>
      <phone>801-662-4710</phone>
      <email>Mark.Fluchel@imail2.org</email>
    </contact>
    <investigator>
      <last_name>Mark N Fluchel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Münster Department of Pediatric Hematology and Oncology</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Rössig, Prof. Dr. Med.</last_name>
      <phone>0049 2518347742</phone>
      <email>rossig@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Rössig, Prof. Dr. Med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo - Centro di Emato-Oncologia Pediatrica</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Rizzari, MD</last_name>
      <phone>0039_039_233</phone>
      <phone_ext>3513</phone_ext>
      <email>c.rizzari@hsgerardo.org</email>
    </contact>
    <contact_backup>
      <last_name>Giusy Sgroi, MSc</last_name>
      <phone>0039_039 233</phone>
      <phone_ext>4915</phone_ext>
      <email>gsgroi@fondazionembbm.it</email>
    </contact_backup>
    <investigator>
      <last_name>Carmelo Rizzari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariacaterina Putti, MD</last_name>
      <phone>0039_049_8213535</phone>
      <email>mariacaterina.putti@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Mariacaterina Putti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu'</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <phone>0039 06 68592678</phone>
      <email>franco.locatelli@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù - UO Reumatologia</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio de Benedetti, MD</last_name>
      <phone>00 39 06 6859 2309 2659</phone>
      <email>fabrizio.debenedetti@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Fabrizio de Benedetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Donna Bambino - U.O.C. Oncoematologia Pediatrica</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Cesare, MD</last_name>
      <phone>0039 045 812 7874</phone>
      <email>simone.cesaro@aovr.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Simone Cesare, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron Servei de Hematologia i Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08900</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Dapena, MD</last_name>
      <phone>0034_934893093</phone>
    </contact>
    <investigator>
      <last_name>Jose L Dapena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Niño Jesús Servicio de Hemato-Oncología Pediátrica</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Sevilla, MD</last_name>
      <phone>0034_915_035</phone>
      <phone_ext>938</phone_ext>
      <email>julian.sevilla@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Julian Sevilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan-Inge Henter, MD</last_name>
      <phone>0046851772484</phone>
      <email>Jan-Inge.Henter@ki.se</email>
    </contact>
    <investigator>
      <last_name>Jan-Inge Henter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital - Department of Haematology</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anupama Rao, MD</last_name>
    </contact>
    <contact_backup>
      <phone>00442074059200</phone>
      <phone_ext>7918</phone_ext>
      <email>Anupama.Rao@gosh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Anupama Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophagocytic lymphohistiocytosis (HLH) previously treated with NI-0501</keyword>
  <keyword>Emapalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

